Kidney Cancer Drugs Industry - Regional Synopsis
North America Market Forecast:
North America industry is set to hold largest revenue share of 35% by 2037, owing to the presence of well-developed healthcare infrastructure. The robust healthcare system facilitates the availability and accessibility of new and innovative kidney cancer drugs. Additionally, the region is a major center for clinical trials and cancer research. This fosters the development of new kidney cancer drugs and drives their availability in the market. The rising prevalence of kidney cancer cases, innovations in cancer drug formulations, and high investments in new product launches by biopharma companies are further fuelling the kidney cancer market growth in North America.
The U.S. kidney cancer drugs market size is poised to witness significant growth till 2037, owing to the rising cases of kidney cancer. According to the American Cancer Society, the U.S. is expected to witness around 81,600 new kidney cancer cases and more than 14,000 deaths by the end of 2024. The majority of people diagnosed with kidney cancer are estimated to be between the age group of 55 and 74. Moreover, comprehensive health insurance coverage and favorable reimbursement policies for cancer treatments facilitate patient access to expensive and innovative therapies, boosting market growth.
Canada is also advancing in the field of cancer treatment due to the presence of several kidney cancer care organizations such as Kidney Cancer Canada, Canadian Cancer Society, and Cancer Care Ontario. Canada represents a substantial market for kidney cancer drugs, with a growing focus on addressing renal cell carcinoma through advanced treatment options. The kidney cancer drugs market growth is driven by increasing incidence rates and the availability of innovative therapies. According to Canadian Cancer Society estimations, around 9,000 individuals in Canada are expected to be detected with kidney and renal pelvis cancer by the end of 2024, out of which 5900 are supposed to be males and 3100 females.
APAC Market Analysis:
The Asia Pacific in kidney cancer drugs market is anticipated to increase at a fast pace through 2037. The rising healthcare expenditures, increasing patient pool in high-potential economies such as China and India, and growing awareness of renal cancer are expected to augment the sales of kidney cancer treatments in the region in the coming years. In India government initiatives on cancer diagnosis and care are set to uplift the profits of kidney cancer drug manufacturers. Indian Cancer Society (ICS) is actively carrying out various cancer awareness programs around the country. According to the Indian Cancer Society (ICS), the cases of cancer are increasing rapidly in India, with kidney cancer constituting 1.3% of the country’s total cancer cases.
According to the World Cancer Research Fund International, China has a high prevalence of kidney cancer across the world. In April 2024, Shanghai Junshi Biosciences Co., Ltd declared that the National Medical Products Administration approved their new drug ‘toripalimab’ for medium to high-risk unresectable or metastatic renal cell carcinoma treatment. Toripalimab in combination with axitinib is approved to be used as the first-line of treatment for renal cancer in China.
